# Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)

> **NCT01437059** · PHASE1 · COMPLETED · sponsor: **Alnylam Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Elevated LDL-Cholesterol (LDL-C)

## Interventions

- **DRUG:** ALN-PCS02
- **DRUG:** Sterile Normal Saline (0.9% NaCl)

## Key facts

- **NCT ID:** NCT01437059
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-03
- **Final completion:** 2012-09
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2012-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01437059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01437059, "Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01437059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*